MorphoSys Future Growth
Future criteria checks 2/6
MorphoSys se prevé un crecimiento anual de los beneficios y los ingresos de 11.4% y 20.6% respectivamente. Se prevé que el BPA sea de grow en 13.2% al año. Se prevé que la rentabilidad de los fondos propios sea de -476% en 3 años.
Key information
51.0%
Earnings growth rate
65.1%
EPS growth rate
| Biotechs earnings growth | 19.2% |
| Revenue growth rate | 21.9% |
| Future return on equity | -453.2% |
| Analyst coverage | Good |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 420 | -15 | N/A | 7 | 4 |
| 12/31/2025 | 325 | -115 | -258 | -226 | 9 |
| 12/31/2024 | 252 | -182 | -296 | -253 | 10 |
| 12/31/2023 | 238 | -190 | -299 | -296 | N/A |
| 9/30/2023 | 261 | 91 | -351 | -343 | N/A |
| 6/30/2023 | 293 | 88 | -337 | -326 | N/A |
| 3/31/2023 | 299 | -73 | -309 | -294 | N/A |
| 12/31/2022 | 278 | -151 | -382 | -367 | N/A |
| 9/30/2022 | 250 | -861 | -436 | -417 | N/A |
| 6/30/2022 | 195 | -851 | -606 | -588 | N/A |
| 3/31/2022 | 174 | -596 | -610 | -583 | N/A |
| 12/31/2021 | 180 | -514 | -508 | -481 | N/A |
| 9/30/2021 | 163 | -150 | -423 | -393 | N/A |
| 6/30/2021 | 143 | -103 | -295 | -246 | N/A |
| 3/31/2021 | 124 | -177 | -255 | -217 | N/A |
| 12/31/2020 | 328 | 98 | -14 | 35 | N/A |
| 9/30/2020 | 303 | 64 | 26 | 63 | N/A |
| 6/30/2020 | 293 | 105 | 98 | 113 | N/A |
| 3/31/2020 | 309 | 153 | 137 | 152 | N/A |
| 12/31/2019 | 72 | -103 | -85 | -81 | N/A |
| 9/30/2019 | 71 | -96 | -68 | -64 | N/A |
| 6/30/2019 | 114 | -42 | -42 | -39 | N/A |
| 3/31/2019 | 87 | -59 | -33 | -31 | N/A |
| 12/31/2018 | 76 | -56 | -35 | -33 | N/A |
| 9/30/2018 | 94 | -27 | -16 | -14 | N/A |
| 6/30/2018 | 54 | -82 | -61 | -48 | N/A |
| 3/31/2018 | 58 | -74 | -68 | -55 | N/A |
| 12/31/2017 | 67 | -70 | -52 | -38 | N/A |
| 9/30/2017 | 52 | -84 | N/A | -52 | N/A |
| 6/30/2017 | 49 | -73 | N/A | -59 | N/A |
| 3/31/2017 | 49 | -68 | N/A | -47 | N/A |
| 12/31/2016 | 50 | -60 | N/A | -47 | N/A |
| 9/30/2016 | 49 | -45 | N/A | -48 | N/A |
| 6/30/2016 | 48 | -40 | N/A | -41 | N/A |
| 3/31/2016 | 48 | -33 | N/A | -35 | N/A |
| 12/31/2015 | 106 | 15 | N/A | -24 | N/A |
| 9/30/2015 | 111 | 27 | N/A | -15 | N/A |
| 6/30/2015 | 116 | 33 | N/A | -3 | N/A |
| 3/31/2015 | 119 | 37 | N/A | -4 | N/A |
| 12/31/2014 | 64 | -3 | N/A | -14 | N/A |
| 9/30/2014 | 61 | -6 | N/A | -15 | N/A |
| 6/30/2014 | 60 | -5 | N/A | 79 | N/A |
| 3/31/2014 | 77 | 7 | N/A | 76 | N/A |
| 12/31/2013 | 78 | 7 | N/A | 89 | N/A |
| 9/30/2013 | 80 | 14 | N/A | 100 | N/A |
| 6/30/2013 | 76 | 16 | N/A | 3 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: 0NDV se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios frente mercado: 0NDV se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: 0NDV se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: 0NDVSe prevé que los ingresos de la empresa (20.6% al año) crezcan más deprisa que los del mercado UK (3.7% al año).
Ingresos de alto crecimiento: 0NDVSe prevé que los ingresos de la empresa (20.6% al año) crezcan más deprisa que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): 0NDV se prevé que no sea rentable en 3 años.